Sarepta, with new Duchenne results, to broach 'possibility' of speedy gene therapy approval

Sarepta Therapeutics on Monday presented new results from a placebo-controlled study of its experimental gene therapy for Duchenne muscular dystrophy, a closely watched treatment that has produced mixed results so far in clinical testing.